SGLT2 Inhibitors Show Similar Cardiorenal Benefits

by | May 14, 2026 | Health

Spread the love
Empagliflozin and dapagliflozin show similar effectiveness in preventing cardiorenal outcomes among patients with type 2 diabetes without prior cardiovascular or renal disease.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments